Cantourage Group SE
Original-Research: Cantourage Group SE (von NuWays AG): BUY

Original-Research: Cantourage Group SE – von NuWays AG

Einstufung von NuWays AG zu Cantourage Group SE

Unternehmen: Cantourage Group SE
ISIN: DE000A3DSV01

Anlass der Studie: Long Note
Empfehlung: BUY
seit: 06.02.2024
Kursziel: 11.00
Kursziel auf Sicht von: 12 Monaten
Letzte Ratingänderung:
Analyst: Christian Sandherr

Cannabis legalization around the corner

Topic: With the approval of the ‘Cannabis Act’, which is now expected to
take place at the beginning of April, Germany is seen to take a big leap
forward in regards to legalizing cannabis. This should translate into a
significant tailwind for players such as Cantourage.

As per consistent and reliable German media reports from ZEIT, dpa and
Berliner Morgenpost, the governing coalition of SPD, Greens and FDP has
finalized the specifics for the legalization of cannabis. The legislation
is scheduled to take effect on April 1st.

Once the “Cannabis Act” becomes effective, Germany will not only allow
adults to own 25 grams of cannabis, grow up to three plants and establish
non-profit cannabis clubs but cannabis will also loose its narcotic drug
status. Cantourage should particularly benefit from the latter as it
significantly simplifies the process of getting a prescription for medical
cannabis. In fact, it should get as easy as getting one for ibuprofen 600.

With this, the number of patients should remain on a stellar growth path at
the expense of the black market (~4m cannabis users as of 2021) and in
favour of established players such as Cantourage. In Canada, the number of
medial cannabis patients grew from 24k in 2015 to 330k in 2018, the year of
the full legalization. Thanks to its broad global supplier network with
more than 60 grower partners, its own recently launched telemedicine
platform, telecan°, and a growing distribution network across Europe, we
regard Cantourage as well positioned to benefit from this change. In fact,
the company looks set to grow sales at a 59% CAGR (2022-25e) while at the
same time reaching a high single-digit EBITDA margins thanks to the
resulting operating leverage.

Ending FY23e on a high note. Following 9M results with € 17.2m sales (+85%
yoy) and EBITDA of € -0.4m, the forth quarter looks set to remain on a
strong growth trajectory: sales +54% yoy to € 7.5m and EBITDA of € 0.6m.
Above all, this should be carried by the ongoing ramp-up, i.e. a gradually
increasing number of fully onboarded cultivators having a product deployed
at pharmacies.

We confirm our BUY rating with an unchanged € 11 PT, based on DCF.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/28823.pdf
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.

Kontakt für Rückfragen
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.
Kontakt für Rückfragen
NuWays AG – Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

——————-übermittelt durch die EQS Group AG.——————-


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.